Patient-Reported Outcomes Among Type 2 Diabetes Mellitus Patients Treated with Dapagliflozin in Triple Therapy Regimen for 52 Weeks.

Patient-Reported Outcomes Among Type 2 Diabetes Mellitus Patients Treated with Dapagliflozin in Triple Therapy Regimen for 52 Weeks. Diabetes Obes Metab. 2015 Nov 5; Authors: Grandy S, Sternhufvud C, Ryden A, Sugg J, Rohwedder K Abstract Patients with T2DM and inadequate glycemic control on combination metformin (MET) and sulfonylurea (SU) were enrolled in a 24-week, double-blind, randomized, placebo-controlled study with a 28-week extension. The EQ-5D, SHIELD Weight Questionnaire-9 (WQ-9), Impact of Weight on Quality of Life-Lite (IWQOL-Lite), and Diabetes Treatment Satisfaction Questionnaire (DTSQ) evaluated health status and health-related quality of life (HRQOL) at baseline and week 52. Patients with dapagliflozin 10 mg + MET + SU (n=108) were compared with patients treated with placebo + MET + SU (n=108), using repeated measures mixed model. EQ-5D visual analog scale scores, IWQOL-Lite and DTSQ scores improved in dapagliflozin and placebo groups from baseline to week 52; however, there was no significant difference between groups (p>0.20). EQ-5D index scores remained the same from baseline to week 52 for dapagliflozin and placebo (p=0.54). A numerically greater proportion of the dapagliflozin group reported improvement in all 9 SHIELD WQ-9 items compared with placebo, and the difference was statistically significant for physical health (p=0.017). Over 52 weeks of therapy, patients maintained their health status and HRQOL when...
Source: Diabetes Metab - Category: Endocrinology Authors: Tags: Diabetes Obes Metab Source Type: research